country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-179267

Copy Link Print Information

FTO-IN-16

FTO-IN-16 (Compound 8a-1), a FTO-IN-15 (HY-179266) prodrug, is a potent FTO inhibitor. FTO-IN-16 suppresses acute myeloid leukemia (AML) cell viability, increases m⁶A levels, downregulates c-Myc and CEBPA, and upregulates ASB2 and RARA. FTO-IN-16 induces apoptosis. FTO-IN-16 demonstrates strong in vivo efficacy in AML mouse xenografts. FTO-IN-16 can be used for the research of AML.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₂₃H₂₃Cl₂N₃O₆
Molecular Weight:508.35

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

FTO-IN-16 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle RAR/RXR Isoform-spezifische Produkte anzeigen :

In Vitro

FTO-IN-16 (0-8 μM; 48 h) downregulates c-Myc and CEBPA (protein and mRNA), and upregulates ASB2 and RARA in multiple AML cells (NB4, MOLM13, MV4-11, HEL, OCI-AML3, NOMO-1, KG-1)^[1].
FTO-IN-16 (0-20 μM; 48 h) induces dose-dependent apoptosis in NB4 cells^[1].
FTO-IN-16 (0-8 μM; 48 h) downregulates c-Myc and CEBPA (protein and mRNA), and upregulates ASB2 and RARA in multiple AML cells (NB4, MOLM13, MV4-11, HEL, OCI-AML3, NOMO-1, KG-1)^[1].
FTO-IN-16 (72 h) exhibits potent antileukemic activity across a panel of AML cell lines, with IC50 values of 5.5 (NB4), 2.3 (MOLM13), 4.4 (KG-1), 3.6 (MV4-11), 4.6 (HEL), 5.2 (OCI-AML3), and 4.7 μM (NOMO-1), respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MOLM13
Concentration:

0, 2, 4, 8 μM
Incubation Time:

24, 48, 72 h
Result:

Induced time-dependent growth inhibition. Significantly inhibited cell growth after 72 h treatment at 8 μM compared to the control.

Cell Proliferation Assay^[1]

Cell Line:

NB4
Concentration:

0, 1, 2, 4 μM
Incubation Time:

7 days
Result:

Induced dose-dependent suppression of colony formation.

Apoptosis Analysis^[1]

Cell Line:

NB4
Concentration:

0, 5, 10, 20 μM
Incubation Time:

48 h
Result:

Induced dose-dependent apoptosis.

Western Blot Analysis^[1]

Cell Line:

NB4, MOLM13, MV4-11, HEL, OCI-AML3, NOMO-1, KG-1
Concentration:

0, 2, 4, 8 μM
Incubation Time:

48 h
Result:

Upregulated tumor suppressors RARA and ASB2. Reduced protein levels of the oncoproteins CEBPA and c-Myc. The downregulation of c-Myc protein was consistently observed across 7 tested AML cell lines. Did not alter the protein levels of FTO itself or other major m6A regulators, including ALKBH5 and METTL3.

Real Time qPCR^[1]

Cell Line:

NB4
Concentration:

0, 4, 8 μM
Incubation Time:

48 h
Result:

Increased ASB2 expression accompanied by decreased c-Myc and CEBPA transcripts.

In Vivo

FTO-IN-16 (30 and 60 mg/kg; i.p.; daily for 9 days) impairs AML progression through m⁶A-mediated transcriptional regulation in an AML mouse xenograft model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female BALB/c nude mice subcutaneously injected with NB4 AML cells^[1]
Dosage:

30 and 60 mg/kg
Administration:

i.p.; daily for 9 days
Result:

Significantly suppressed tumor growth in a dose-dependent manner. Showed no significant body weight loss or organ toxicity. Resulted in upregulation of tumor suppressors (RARA, ASB2) and downregulation of oncoproteins (CEBPA, c-Myc). Showed a marked increase in global RNA m⁶A modifications.

Related Protocols :

Chemical Information

Molecular Weight 508.35
Formel C₂₃H₂₃Cl₂N₃O₆
SMILES

O=C(C1=CC=CC=C1NC2=C(C=C(C=C2Cl)C(NCCNC(/C=C/C(OCC)=O)=O)=O)Cl)OC
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang X, et al. Structure-Based Design of a Highly Potent Dual-Competitive FTO Inhibitor for Targeted m6A Demethylase Inhibition in AML. J Med Chem. 2025 Nov 13;68(21):22779-22798. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen